MDAI
5,6-methylenedioxy-2-aminoindane
Viewing r1 — May 3, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
MDAI (5,6-methylenedioxy-2-aminoindane) — sparkle, mindy — is a synthetic empathogen of the aminoindane class. It is a structural analog of MDA, designed to preserve warm emotional openness while eliminating neurotoxicity. It works by flooding the brain with serotonin and norepinephrine,[1] producing prosocial warmth without stimulant drive.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
MDMA, MDA, 6-APB +3 moreMDMA, MDA, 6-APB, 5-MAPB, 5-APB, methylone show less
David Nichols synthesized MDAI in 1990 as a research tool for studying empathogenic effects without serotonin neurotoxicity.[2] It remained an obscure laboratory compound for seventeen years, then surged onto European markets after the UK banned mephedrone in 2010.[3] Today it carries no international scheduling and remains available through some online vendors, though national laws vary widely.[4]
Subjective effects include emotional warmth, empathy, prosocial openness, mild mood elevation, and body warmth. The experience is distinctly gentle — closer to quiet emotional closeness than the rushing stimulant energy of MDMA, and noticeably stronger in social settings than alone.[5] Nausea during onset, a mild mood dip afterward, and slight blood pressure elevation are common.[6]
No physical dependence has been documented, and no confirmed death from MDAI alone exists — every fatality involved other serotonergic drugs.[7][8] Combining MDAI with MAOIs, SSRIs, or other empathogens floods the brain with serotonin beyond safe limits, causing overheating, muscle rigidity, and potentially death. The evidence base is extremely sparse — nearly everything known comes from a single small human study and one animal paper.[6][9]
History[edit]
Discovery
David Nichols synthesized MDAI in 1990, publishing it as "compound 3a" in the Journal of Medicinal Chemistry.[2] The goal was an MDMA-like compound that retained empathogenic effects without serotonin neurotoxicity — and it worked: at doses where MDMA damaged serotonin neurons in rat brains, MDAI caused no measurable harm.[2]
From laboratory to legal high
MDAI sat unused for seventeen years before appearing on European recreational markets around 2007.[7][3] When the UK banned mephedrone in April 2010, demand for legal alternatives surged, and MDAI — sold as "sparkle" and "mindy" — filled the gap.[3] Its reputation as non-neurotoxic, drawn entirely from the 1990 Nichols paper, became its primary selling point in online drug communities.[3]
Scheduling and present status
The first UK deaths involving MDAI appeared in 2011–2012, all in polydrug contexts.[7] National scheduling followed: China acted first in September 2010, US states followed independently, and the UK's Psychoactive Substances Act covered MDAI from 2016.[10] As of 2026, MDAI carries no international UN scheduling and remains available through some online vendors in unregulated markets.[4]
MDAI's street names "sparkle" and "mindy" emerged during the 2010–2012 UK legal high era. It was also sold in combination products — most notably "Pink Panthers," which blended MDAI with 2-aminoindane.[11] Its cultural identity was built almost entirely on the promise of Nichols's non-neurotoxicity finding: one data point that became the compound's entire brand.
Chemistry[edit]
Structure
MDAI belongs to the aminoindane family — compounds built on an indane ring (a five-membered ring fused to benzene) with an amine group attached.[2]
It is a structural analog of MDA, sharing the same methylenedioxy bridge found in MDMA — the feature that drives its serotonergic activity. Its molecular formula is C₁₀H₁₁NO₂ (molecular weight 177.20 g/mol), with a lipophilicity that allows it to cross readily into the brain.[6]
Pharmacology[edit]
Mechanism of action
MDAI forces stored serotonin and norepinephrine out of neurons and into the synapse — the same basic mechanism as MDMA.[1] It releases serotonin far more powerfully than dopamine — roughly 42 times the potency difference — which is why the experience produces emotional warmth without stimulant drive or compulsive redosing urge.[12][1]
Neurotoxicity profile
The original 1990 study found MDAI did not damage serotonin neurons in rats at doses where MDMA caused significant harm.[2] This "non-neurotoxic" label rests on a single acute-dose animal experiment — no replication studies or human neuroimaging data have been published. The characterization remains provisional.
Pharmacokinetics
In the only human study, MDAI appeared in blood within 20 minutes of an oral dose and remained detectable for at least 4 days in blood and 6 days in urine — longer than typical MDMA detection windows.[6] No formal half-life has been calculated, and it is unknown which liver enzymes break it down.
Neuroscience[edit]
Where it acts
MDAI's serotonin release is predicted to reduce the brain's threat-detection circuitry, increasing feelings of safety and social openness — the same neural circuits engaged by MDMA. It also activates oxytocin pathways, which enhance bonding and trust. Elevated prolactin and cortisol confirmed in human subjects reflect significant serotonergic neuroendocrine activation.[6]
Entactogenic window
Entactogens produce their characteristic prosocial effects when serotonin activity is high relative to dopamine. MDAI sits deeper in this zone than MDMA itself[1] — which explains why users describe it as "MDMA without the push."[5] The emotional warmth is present; the urgency is not.
Rats show overheating at standard doses,[9] while human subjects in controlled conditions showed no temperature increase[6] — the discrepancy is unexplained. MDAI also accumulated in lung tissue in rats at concentrations exceeding brain levels,[9] and whether repeated use could cause pulmonary or cardiac valve effects has never been assessed.
Subjective Effects[edit]
MDAI produces a slow, gentle empathogenic state — emotional warmth and prosocial openness that unfold gradually, without the physical tension or stimulant urgency of MDMA. The experience is strongly shaped by context: social settings amplify it significantly, while solitary use often feels subtle or underwhelming.
Relative to MDMA, MDAI occupies a quieter register — comparable emotional depth at adequate doses, but less euphoric push, less physical activation, and substantially less compulsive quality.[5] The shorter duration and lighter cardiovascular load reinforce the impression of a softer, more contained experience.[6]
Effect Grid
At common doses (approximately 100–175 mg oral), the full entactogenic experience emerges: pronounced emotional openness, empathy enhancement, feelings of closeness and connection with others, and a warm, content mood state. Music enhancement is marked. The experience is described as MDMA-like but with less stimulant "push" — a gentler, more purely empathogenic quality.
Physically, blood pressure elevation is expected based on human data at this range. Pupil dilation is pronounced. Bruxism (jaw clenching), mild nausea on onset, and slight temperature sensitivity are possible. Heart rate and body temperature were not elevated in the only controlled human study at this dose range.
Peak effects last 1–2 hours, with total subjective duration of 3–5 hours. Sleep is unlikely for at least 4–5 hours post-ingestion.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual haze / noise · Color enhancement · Visual acuity enhancement · Tracers
Sedation · Spontaneous body sensations · Tactile euphoria · Appetite suppression · Bruxism · Sexual arousal suppression · Physical fatigue · Excessive sweating · Dehydration sensation · Tingling / electric sensations · Dry mouth · Muscle relaxation · Bodily heaviness · Nausea · Increased urination · Dizziness · Headache · Pain suppression · Wakefulness
Bruxism · Sexual arousal suppression · Physical fatigue · Excessive sweating · Dehydration sensation · Tingling / electric sensations · Dry mouth · Muscle relaxation · Bodily heaviness · Nausea · Increased urination · Dizziness · Headache · Pain suppression · Wakefulness
Cognitive fatigue · Introspection enhancement · Aesthetic enhancement · Cognitive impairment · Thought deceleration · Motivation suppression · Focus suppression · Humor enhancement · Information processing suppression · Confusion
Thought deceleration · Motivation suppression · Focus suppression · Humor enhancement · Information processing suppression · Confusion
Irritability · Anhedonia · Catharsis
Emotional susceptibility · Communication enhancement
Timeline
First alerts appear 20–60 minutes after ingestion: a subtle shift in mood, faint bodily warmth, and mild restlessness. MDAI was first detected in serum approximately 20 minutes post-dose.
Building warmth, emerging emotional openness, and increasing sociability. Mild nausea or stomach discomfort may occur during this phase. Pupil dilation becomes apparent.
Full entactogenic effects: emotional warmth, empathy, music enhancement, and feelings of closeness. Blood pressure is elevated. Unlike MDMA, heart rate and body temperature are not typically increased.
Effects remain present but gradually diminish in intensity. Emotional openness and sociability persist. Physical stimulation wanes, and a gentle contentment replaces the peak intensity.
Gradual return to baseline. Residual warmth and mild mood elevation may linger. Fatigue begins to set in as serotonin stores are transiently depleted.
Residual mood changes may persist for hours to a day. Some individuals report a gentle afterglow; others experience low mood and fatigue consistent with transient serotonin depletion.
⚠ Do not drive or operate machinery for the remainder of the day following MDAI use, as residual cognitive and psychomotor impairment may persist beyond subjective awareness of effects.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- None
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- MDMA · MDA · 6-APB
Toxicity
No confirmed human death from MDAI alone exists — every fatality involved other serotonergic drugs.[7][8][13] In animal studies, all rats survived 40 mg/kg orally, while the same dose injected killed 90% within 15 minutes.[9] Oral administration carries a substantially wider safety margin than injection.
Liver toxicity
Laboratory testing classified MDAI among the most toxic compounds tested against human liver cells — exceeding MDMA, mephedrone, and methylone.[14] No human liver injury cases have been reported, but pre-existing liver impairment increases theoretical risk.
Temperature regulation
MDAI caused overheating in crowded rats, with the effect amplified by group conditions.[9] Human subjects showed no temperature increase under controlled conditions.[6] Hot, crowded environments — clubs, festivals — may unmask a hyperthermic risk not apparent in clinical settings.
Blood disorders
A user of "Pink Panthers" — a product containing MDAI and 2-aminoindane — developed reduced oxygen-carrying capacity in the blood.[11] Benzocaine contamination likely contributed.
Psychological risks
No systematic data on MDAI-specific psychological harms exist. At high doses, acute anxiety, confusion, and agitation are expected. Signs of serotonin overload — agitation, overheating, muscle rigidity, rapid heart rate — appeared in rat behavioral tests at all doses[9] and were implicated in the earliest UK deaths.[7]
Post-use mood dip from temporary serotonin depletion is expected, though severity and duration have not been characterized for MDAI specifically.
Tolerance and dependence
No physical dependence has been documented. Tolerance builds through depletion of serotonin stores — once depleted, the drug has less to release and effects diminish, making repeated dosing within a short window self-limiting rather than escalating.
MDAI showed reinforcement in mice,[15] but its very weak dopamine activity predicts substantially lower abuse liability than stimulants.[12] Cross-tolerance with MDMA and other entactogens is assumed but unconfirmed.
Drug interactions
Every documented MDAI fatality involved other serotonin-active substances. Combining it with other serotonin releasers — MDMA, benzofurans like 5-APB, other aminoindanes — stacks serotonergic load and risks dangerous overload.[8][13] One Belgian fatality involved four serotonergic compounds simultaneously.[8]
MAOIs are an absolute contraindication: they prevent the brain from breaking down the serotonin that MDAI releases, creating dangerously sustained serotonin levels — a direct route to lethal serotonin syndrome. Tramadol is also classified as a lethal combination: it inhibits serotonin reuptake and has weak releasing properties, creating clear mechanistic risk.safety citation needed
Contraindications
MAOI use is an absolute contraindication. Concurrent use of other serotonergic substances — SSRIs, SNRIs, other entactogens, serotonergic psychedelics — is a relative-to-absolute contraindication depending on specific agents and doses.[7][8][13]
Pre-existing heart conditions are a relative contraindication: MDAI elevates blood pressure[6] and releases norepinephrine, placing stress on the cardiovascular system.[12] Liver impairment is a relative contraindication given the strong laboratory hepatotoxicity signal.[14] History of psychotic or seizure disorders warrants caution — serotonin releasing agents can trigger episodes, and MDAI disrupted sensorimotor gating at all tested doses in rats.[9] Pregnancy and breastfeeding: no data exist, but exposure is contraindicated for any centrally active monoamine releaser.
Harm Reduction[edit]
Forms & Identification
MDAI is most commonly encountered as a white to off-white crystalline powder. Combination products have been documented — notably "Pink Panthers," which blended MDAI with 2-aminoindane[11] — meaning labeled products may contain additional active compounds. Reagent testing confirms identity but not purity or the absence of adulterants.
Since every documented fatality involved serotonergic polydrug combinations, confirming the contents of any sample is the single most consequential harm reduction step for this substance.
Guidelines
- Test substance identity with reagent kits before use
- Start with a low dose and wait at least 90 minutes before considering redosing — onset can be gradual
- Avoid combining with any other serotonergic substance (other empathogens, SSRIs, MAOIs, tramadol)
- Stay hydrated but do not overdrink — sip water rather than consuming large volumes
- Maintain access to cool environments and fresh air, particularly in club or festival settings
- Have a sober companion present, particularly at higher doses or first experiences
- Allow at least 4–6 weeks between uses to permit serotonin recovery
- Do not redose repeatedly in a single session — diminishing returns from serotonin depletion increase side effects without proportionally increasing desired effects
Set & Setting
MDAI's effects are strongly shaped by context. Social, comfortable environments amplify the empathogenic quality; solitary settings often produce underwhelming results.[5] Crowded, hot environments may increase overheating risk based on animal data showing socially-augmented hyperthermia.[9] A familiar, temperate environment with trusted company represents the lowest-risk context.
Aftercare & integration. The post-experience period typically brings a mild mood dip from temporary serotonin depletion. Prioritize sleep, nutritious food, and gentle social contact in the 24–48 hours following use. Avoid intense physical exertion on the day following use.
MDAI's empathogenic quality may surface emotional material worth processing. If difficult feelings or memories arose, journaling or a conversation with a trusted person can help. Persistent low mood beyond 3–5 days warrants professional attention.
Recovery & Support
MDAI's weak dopamine activity makes compulsive use patterns less likely than with stimulants, but psychological habituation to the emotional state is possible with frequent use. If use has become a regular way of managing social anxiety or emotional numbness, that pattern is worth examining.
Peer support communities and harm reduction organizations can offer non-judgmental guidance. Professional support is appropriate when use frequency escalates, when sober social functioning deteriorates, or when the post-use mood dip extends into persistent depression.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Signs that require immediate help include uncontrollable muscle rigidity or jerking, extremely high body temperature (skin hot to touch), seizures, confusion progressing to unconsciousness, and blue-tinged lips or skin. These may indicate serotonin syndrome or cardiovascular crisis — both are medical emergencies.
Immediate steps:
- Call emergency services immediately
- Move the person to a cool, quiet area
- Remove excess clothing to help cool them
- Place in the recovery position if unconscious but breathing
- Do not give food or drink to an unconscious person
- Do not restrain someone having seizures — clear the area around them
What to tell the dispatcher: Name the substance (MDAI/aminoindane), approximate amount taken, time of ingestion, any other substances used, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution for drug-related emergencies.
Legal Status[edit]
MDAI carries no international scheduling under the United Nations drug conventions,[4] but national laws vary substantially — in some jurisdictions it may be prosecuted under structural analog legislation.[10]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International | No control | Not scheduled under UN drug conventions[4] |
| United States (federal) | Unscheduled | Federal Analogue Act may apply; Louisiana Schedule I (June 2013); Minnesota Schedule I (August 2012)[10] |
| United Kingdom | Psychoactive Substances Act 2016 | Supply and production prohibited; personal possession not an offence[16] |
| China | Category I psychotropic | Controlled since September 2010[10] |
| Finland | Controlled | Banned December 2014 under NPS regulation[5] |
| Denmark | Controlled | Scheduled September 2015[5] |
| EU (multiple states) | Controlled | Cyprus, Czech Republic, Estonia, Hungary, Italy, Lithuania, Portugal, Sweden[5] |
| Canada | Not specifically scheduled | No specific scheduling confirmed[10] |
| Australia | Unknown | Not confirmed in available sourcescitation needed |
| Germany | Unknown | Not confirmed in available sourcescitation needed |
Legal status changes frequently and varies by jurisdiction. This information is not legal advice — verify current local laws before obtaining or using this substance.
references
- [1] ^abcdSimmler LD, Rickli A, Schramm Y, Hoener MC, Liechti ME (2014) Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. — Biochemical Pharmacology doi:10.1016/j.bcp.2014.01.024
- [2]
- [3] ^abcdGallagher CT, Assi S, Stair JL, Fergus S, Corazza O, Corkery JM, Schifano F (2012) 5,6-Methylenedioxy-2-aminoindane: from laboratory curiosity to 'legal high'. — Human Psychopharmacology doi:10.1002/hup.1255
- [4]
- [5]
- [6] ^abcdefghiAngerer V, Schmid Y, Franz F, Gnann H, Speer JM, Gnann A, Helmecke S, Buchwald A, Brandt SD, Passie T, Liechti ME, Auwärter V (2024) Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study. — Drug Testing and Analysis doi:10.1002/dta.3622